There is no evidence to support the use of beta2-agonists in children and adults with acute cough who do not have evidence of airflow restriction, a Cochrane review concludes.
The analysis of seven trials by Cochrane Acute Respiratory Infections Group noted that treatment might reduce symptoms, including cough.
However the potential benefits were not well supported by data and “must be weighed against the adverse effects of these medications, such as shaking, tremor and nervousness,” it concluded.